Biomarker Monitoring Framework for Safe Tirzepatide Use with Hypothyroidism Establishing baseline biomarkers before starting tirzepatideincluding TSH, free T4, free T3, TPO antibodies, and metabolic panelprovides a clinical anchor for evaluating treatment response
Its important that you take everything at your own pace and regularly check in with your clinician, who can help you monitor your progress
The practical implication: if you have a history of gastroparesis or symptoms suggesting poor gastric emptying (persistent nausea, chronic bloating, vomiting of undigested food hours after eating), this needs to be discussed with your doctor before starting tirzepatide or during any dose increase
GLP-1 agonists work on leptin and ghrelin, impacting hunger and satiety signaling
To support adherence, consider implementing practical reminder strategies